News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
86,926 Results
Type
Article (2691)
Company Profile (18)
Press Release (84216)
Multimedia
Podcasts (2)
Webinars (3)
Section
Business (29678)
Career Advice (29)
Deals (5126)
Drug Delivery (2)
Drug Development (10290)
Employer Resources (3)
FDA (2040)
Job Trends (1068)
News (43406)
Policy (3899)
Tag
2027 BioCapital Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Beach Standard (2)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (1)
Academia (140)
Accelerated approval (8)
ADA (4)
Adcomms (5)
Allergies (33)
Alliances (9144)
ALS (24)
Alzheimer's disease (207)
Antibody-drug conjugate (ADC) (170)
Approvals (2223)
Artificial intelligence (50)
ASCO (44)
Autoimmune disease (65)
Automation (3)
Bankruptcy (13)
Belgium (2)
Best Places to Work (794)
BIO (12)
Biologics (11)
BIOSECURE Act (5)
Biosimilars (108)
BioSpace Insights (1)
Biotechnology (18)
Bispecific (9)
Bladder cancer (35)
Brain cancer (10)
Breast cancer (73)
Cancer (886)
Cardiovascular disease (40)
Career advice (22)
CAR-T (38)
CDC (3)
CDMO (16)
Celiac Disease (4)
Cell therapy (155)
Cervical cancer (5)
Clinical research (9616)
Collaboration (432)
Commercialization (13)
Compensation (84)
Complete response letters (16)
COVID-19 (299)
CRISPR (8)
C-suite (190)
Cystic fibrosis (10)
Data (1232)
Depression (19)
Dermatology (26)
Diabetes (81)
Diagnostics (693)
Digital health (8)
Drug discovery (53)
Drug pricing (2)
Duchenne muscular dystrophy (53)
Earnings (9660)
Editorial (3)
Employer resources (3)
ESMO (66)
Events (10224)
Executive appointments (138)
Eye disease (1)
FDA (2719)
Fibrodysplasia Ossificans Progressiva (2)
Frontotemporal dementia (3)
Funding (238)
Gene editing (19)
Generative AI (1)
Gene therapy (90)
GLP-1 (102)
Government (293)
Grass and pollen (1)
Guidances (49)
Healthcare (1480)
Hematology (21)
HIV (7)
Huntington's disease (4)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (30)
Immunology and inflammation (25)
Immuno-oncology (18)
Indications (39)
Infectious disease (334)
Inflammatory bowel disease (43)
Inflation Reduction Act (1)
Influenza (15)
Intellectual property (50)
Interviews (6)
IPO (1968)
Job creations (301)
Job search strategy (19)
JPM (5)
Kidney cancer (3)
Kidney disease (16)
Labor market (5)
Layoffs (27)
Legal (1010)
Licensing (29)
Liver cancer (24)
Longevity (3)
Lung cancer (160)
Lung diease (3)
Lymphoma (87)
Machine learning (3)
Management (2)
Manufacturing (196)
Marketing (11)
MASH (20)
Medical device (1252)
Medtech (1273)
Mergers & acquisitions (3416)
Metabolic disorders (160)
mRNA (16)
Multiple sclerosis (28)
Multispecific (1)
NASH (1)
Neurodegenerative disease (51)
Neuropsychiatric disorders (7)
Neuroscience (417)
NextGen: Class of 2026 (356)
Non-profit (85)
Now hiring (4)
Obesity (48)
Opinion (5)
Ovarian cancer (41)
Pain (35)
Pancreatic cancer (37)
Parkinson's disease (59)
Partnered (4)
Patents (93)
Patient recruitment (112)
Patient selection (20)
Peanut (2)
People (6872)
Peptides (1)
Pharmaceutical (2)
Pharmacy benefit managers (5)
Phase 1 (2935)
Phase 2 (4166)
Phase 3 (3496)
Pipeline (1882)
Policy (18)
Postmarket research (262)
Preclinical (972)
Press Release (3)
Prostate cancer (34)
Psychedelics (1)
Radiopharmaceuticals (31)
Rare diseases (152)
Real estate (712)
Recruiting (1)
Regenerative medicine (6)
Regulatory (3543)
Reports (11)
Research institute (160)
Resumes & cover letters (3)
Rett syndrome (1)
RNA editing (3)
RSV (4)
Schizophrenia (30)
Series A (56)
Series B (30)
Service/supplier (2)
Sickle cell disease (14)
Special edition (2)
Spinal muscular atrophy (10)
Sponsored (4)
Startups (526)
Stomach cancer (2)
Substance use disorders (2)
Supply chain (17)
Switzerland (5)
Tariffs (2)
The Weekly (2)
Vaccines (70)
Venture capital (12)
Weight loss (23)
Women's health (11)
Date
Last 7 days (110)
Last 30 days (322)
Last 365 days (3617)
2026 (3033)
2025 (3415)
2024 (4158)
2023 (4930)
2022 (8426)
2021 (7864)
2020 (7025)
2019 (4553)
2018 (3513)
2017 (4160)
2016 (3675)
2015 (4538)
2014 (3378)
2013 (2873)
2012 (3006)
2011 (3149)
2010 (2939)
Location
Africa (102)
Alabama (5)
Arizona (14)
Arkansas (1)
Asia (23192)
Australia (2543)
California (1636)
Canada (599)
China (630)
Colorado (11)
Connecticut (41)
Delaware (23)
Europe (14810)
Florida (153)
Georgia (19)
Hawaii (1)
Idaho (1)
Illinois (61)
India (69)
Indiana (40)
Japan (400)
Kansas (5)
Kentucky (1)
Louisiana (2)
Maine (4)
Maryland (220)
Massachusetts (1038)
Michigan (13)
Minnesota (49)
Missouri (4)
Nebraska (3)
Nevada (18)
New Hampshire (1)
New Jersey (673)
New Mexico (1)
New York (355)
North Carolina (154)
Northern California (725)
Ohio (7)
Oklahoma (1)
Oregon (1)
Pennsylvania (268)
Puerto Rico (1)
Rhode Island (1)
South America (117)
South Carolina (1)
Southern California (755)
Tennessee (6)
Texas (101)
United States (5018)
Utah (40)
Vermont (1)
Virginia (78)
Washington D.C. (5)
Washington State (89)
Wisconsin (11)
Wyoming (1)
86,926 Results for "tilt biotherapeutics ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
TILT Biotherapeutics Presents Encouraging Phase 1b Results in Ovarian Cancer at ESMO 2026
October 26, 2026
·
4 min read
TILT Biotherapeutics Presents Clinical Data on TILT-123 in Ovarian Cancer at ASCO 2024
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announces that it will present two abstracts at the American Society of Clinical Oncology Annual Meeting 2024.
May 28, 2024
·
4 min read
Press Releases
TILT Biotherapeutics Announces Closing of USD 25 Million Series B Financing
May 13, 2025
·
4 min read
Press Releases
Northwest Biotherapeutics Announces Expansion of Its Technical Team
October 26, 2026
·
5 min read
Press Releases
First Tracks Biotherapeutics Announces $200 Million Private Placement
October 15, 2026
·
3 min read
TILT Biotherapeutics Presents Clinical Data on TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer at AACR 2024
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies presented promising preliminary safety and efficacy data from their ongoing Phase I clinical trial in platinum resistant or refractory ovarian cancer patients at the American Association for Cancer Research Annual Meeting 2024.
April 10, 2024
·
4 min read
Press Releases
Genetix Biotherapeutics Appoints Meredith Manning as Chief Commercial Officer
October 19, 2026
·
2 min read
TILT Biotherapeutics Announces Positive Clinical Data on Lead Asset TILT-123 at Society for Immunotherapy of Cancer 2023
TILT Biotherapeutics presented Phase I data on its TILT-123 monotherapy, a T-cell activating oncolytic virus for advanced solid tumor patients, in a late-breaking poster at the Society for Immunotherapy of Cancer 2023 conference.
November 6, 2023
·
4 min read
Press Releases
Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK®
October 27, 2026
·
8 min read
TILT Biotherapeutics Awarded USD 2M Grant from US Department of Defense for Ovarian Cancer Immunotherapy Research
TILT Biotherapeutics announces it has been selected by the U.S. Department of Defense, America’s largest government agency, to receive a USD 2M grant for a three-year project on treatment for ovarian cancer using the company’s TILT-123 asset.
February 14, 2024
·
4 min read
1 of 8,693
Next
